Navigation Links
Derma Sciences Raises $6.1 Million Through Private Placement
Date:4/1/2008

Funds will be used to accelerate sales force expansion

PRINCETON, N.J., April 1, 2008 /PRNewswire-FirstCall/ -- Derma Sciences Inc (OTC Bulletin Board: DSCI), a provider of advanced wound care products, said that its MEDIHONEY(TM) Wound & Burn Dressing with Active Leptospermum Honey has been well received by its target audience, and the Company believes strongly in the potential that it offers for rewarding growth. As a result, the Company intends to accelerate the expansion of its sales force and to broaden the scope of its licensing agreement with Comvita New Zealand, Ltd, its commercialization partner for MEDIHONEY. To facilitate this, the Company entered into securities purchase agreements with several accredited existing and new investors in connection with a private placement of common stock and warrants. Under the terms of the agreement, Derma will receive $6.1 million in gross proceeds from the sale of 6.1 million shares of its common stock and approximately 3.1 million warrants with an exercise price of $1.20. Subject to the satisfaction of customary closing conditions, the transaction is expected to close on or about April 2, 2008.

Aside from the sales force expansion and potentially a broadened license agreement relating to MEDIHONEY, net proceeds from the transaction will be also used for working capital as well as for general corporate purposes. Pending such uses, the proceeds are expected to temporarily pay down the Company's existing revolving credit facility. The offering was conducted in reliance on Section 4(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated there under.

Chairman and CEO Ed Quilty commented, "MEDIHONEY has the potential to improve the quality of life for people with hard-to-heal wounds that are a result of diabetes, vascular insufficiencies, and pressure ulcers -- the bane of nursing home patients. We also believe it will play an important role around the globe as clinicians lo
'/>"/>

SOURCE Derma Sciences Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. American Academy of Dermatology Issues Statement Urging the Public to be Sun Smart(SM)
2. Derma Sciences to Report 2007 Fourth Quarter and Year-End Results on April 1, 2008
3. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
4. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
5. Lynchburg, VA Dermatologist Janet G. Hickman, MD Honored With Rose Hirschler Award from Womens Dermatologic Society
6. Suzanne M. Connolly, MD Named 2008-2009 President of Womens Dermatologic Society
7. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
8. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
9. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
10. Founding Father of Modern Cosmetic Dermatology Seeks to Warn Public of Misrepresented Data and Inappropriate Use of Botox
11. DermTech Adds Allan C. Halpern, MD, Chief of Dermatology at Memorial Sloan- Kettering Cancer Center, to Companys Melanoma Advisory Board

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ew Directors Represent Diverse Healthcare Stakehol...swire/ -- The membership of the National Quality F...f Directors and reappointed four current Board mem... of healthcare stakeholders, including consumers, ...d community healthcare. ,, The newly elected B...
(Date:12/2/2009)...ec. 2 Independence Blue Cross (IBC... with Lincoln Financial Group. IBC will be the pri...y 10,000 Lincoln Financial Group employees, retire...ncoln plan offerings will include the PPO option a...w I speak for all of us at Independence Blue Cross...
(Date:12/2/2009)...ers from the California Institute of Technology (C...the first time, the previously mysterious process ... are added by enzymes called ubiquitin ligases to ...ains tag target proteins for destruction by protei...hat ubiquitin ligases build ubiquitin chains very ...
(Date:12/2/2009)...ial congress of the European Association of Echoca...ean Society of Cardiology, where techniques of non..., New case reports will be presented at this year... the role of this new technology. , Now, with s... likely that non-invasive imaging will gain more i...
(Date:12/2/2009)... First Aid has been a top name in the medical supp...lity products, professional staff, and a keen unde...irst Aid has established itself as a provider of g...s a first aid supplies distributor. The distinguis...ter into its next phase with the redesign and laun...
Breaking Medicine News(10 mins):Health News:National Quality Forum Members Elect Nine Directors to Board 2Health News:National Quality Forum Members Elect Nine Directors to Board 3Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 4Health News:Media alert: EUROECHO 2009 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3
...nicians who don,t know about studies won,t use fin...3 (HealthDay News) -- About 25 percent of practici... two major federal government-funded clinical tria...s and rheumatologists, also found that many clinic...
...ptians may have been using herb-spiked drink for h...3 (HealthDay News) -- The old adage, "take a glass...eded more than 5,000 years ago in ancient Egypt, a...e wine had been steeped in herbs including balm, c...
... KINGSTON, R.I. April 14, 2009 Most fish rely pr... but a University of Rhode Island biologist and he...ican cichlids feeds by using its lateral line sens... along the side of the body of a fish, around its ...
...emonstrates Potential Benefits of Stimulus Package...l care patients at seven Resurrection Health Care ...ications and have extended intensive care unit (IC...08 at 13 Resurrection ICUs, presented last week at...
...T. LAUDERDALE, Fla., April 13 MEDmarketplace.co...me a member of its Board of Directors. MEDmarketpl...based marketplace for buying and selling surplus ...Health Alliance and Premier, Inc, that has a major...
... NEW YORK, April 13 The Advertising Council, in...he launch of a new series of public,service advert...e Els, and his,six year old son, Ben, designed to ...ildren. , , To view the Multimedia News Release...
Other Medicine News:Health News:Awareness of Alternative Therapies May Be Lacking 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 3Health News:Fish researcher demonstrates first 'non-visual feeding' by African cichlids 2Health News:Resurrection Health Uses Information Technology to Address Critical Care Crisis 2Health News:Alan Weinstein Joins the Board of Directors at MEDmarketplace.com 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 4
(Date:12/2/2009)...ec. 2 Hospira, Inc. (NYS...tion and medication delivery technologies, announc... TheraDoc, a clinical informatics company that dev...o leading products, Infection Control Assistant(TM...anding portfolio of medication safety and infectio...
(Date:12/2/2009)...YORK, Dec. 2 Interleukin... Medical Center announced findings from a study pe...he genetics of osteoarthritis have been published ...als of Rheumatic Diseases and is available at htt... . Results from the study highlight importance...
(Date:12/2/2009)...RNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NV... the first stage of a two-stage pivotal Phase II s...he company,s 2009 H1N1 virus-like particle (VLP) p...this study in collaboration with Avimex Laboratori...e in Mexico and potentially other countries. ,,...
Breaking Medicine Technology:Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings 2Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings 3Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings 4Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings 5Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 2Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 3Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 4NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48 Year Exemplary Record of Quality 54443 1Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48 Year Exemplary Record of Quality 54443 2Two Texas Dental Students Receive One time Scholarships from United Concordia Dental 54440 1Two Texas Dental Students Receive One time Scholarships from United Concordia Dental 54440 2Thomson Reuters Invites You to the First Latin American Forum Covering the Pharmaceutical Industry 54437 1Thomson Reuters Invites You to the First Latin American Forum Covering the Pharmaceutical Industry 54437 2
... 28 Aida,Pharmaceuticals, Inc. (OTC Bulletin Boar...essfully completed Phase II field testing of its,a...ecade of research,Rh-Apo2L is intended to be a new... by genetic engineering. The drug is designed as a...ancer cells. Assuming successful,completion of all...
...Phase III Program in First Half of 2008, LEXINGTO...Nasdaq: IDEV ) today announced positive results f...nts with acromegaly, a,disorder characterized by e...nsulin- like growth factor 1 (IGF-1). The implant ...to deliver effective levels of octreotide for,six ...
Other Medicine Technology:Aida Announces Completion of Anti-Cancer Drug Phase Two Testing 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 3Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 4Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 5
...sist is a custom wrist orthotic designed to limit ... the patient's maximum range-of-motion. It incorpo...n-resistance attachment. , ,Indications: , Wrist...riangular fibrocartilage complex , Coles fractur...
Universal Wrist/Forearm Splint
Suede Wrist Lacer Splint
Westport Lacing Wrist Brace
Medicine Products: